This book brings together leading international experts to discuss recent advances in functional studies on key proteins and protein complexes involved in each synaptic vesicle phase. These include proteins that control the final step of neurotransmitter release, in response to a neural signal, and the first step of vesicle endocytosis, which helps maintain stable neurotransmitter release in response to unceasing neural signals arriving at presynaptic terminals. Neural networks transmit input and output signals of action potentials using chemical synapses. The strength of the signal from one to another neuron can be tuned by the neural signal itself as it induces Ca2+ entry and by other neurons' signals that modify Ca2+ entry through voltage-gated Ca2+ channels at the active zone, where chemical neurotransmitters are released from synaptic vesicles via exocytosis. Synaptic vesicles are docked and primed at the active zone prior to exocytosis and are endocytosed after exocytosis for reuse at a small presynaptic terminal. Recycled vesicles are refilled with transmitters and stored for a future round of exocytosis. Thus, synaptic vesicles in presynaptic terminals go through various phases. Each vesicle phase is well orchestrated by numerous proteins and advance step-by-step with neural activities. The fine regulations of synaptic vesicle phases by numerous proteins is an exciting subject, and systematic, well-organized explanations in this book will help the reader easily learn about complicated molecular mechanisms in presynaptic terminals.

This book will bring together leading international experts to discuss recent advances in basic scientific knowledge regarding the regulation of presynaptic Ca2+ channels. Importantly, Ca2+ channels represent one of the most widely modulated proteins in the body, being the target of a range of effector pathways and drugs; this range will be fully represented here. A number of therapeutic drugs target the Ca2+ channel complex, including the anti-epileptic gabapentinoid and analgesic ziconotide drugs and the pharmaceutical industry is searching for Ca2+ channel blocking drugs, particularly in the pain, epilepsy, ataxia and migraine areas. Such potential future therapies will be discussed here. Scientific disciplines will focus on electrophysiological studies, but will extend to neuroscience, genetics and biochemical areas. The work described will represent advances at the cutting edge of current neuroscience research and is timely and highly appropriate for the Springer book series.

This book will bring together leading international experts to discuss recent advances in basic scientific knowledge regarding the regulation of presynaptic Ca2+ channels. Importantly, Ca2+ channels represent one of the most widely modulated proteins in the body, being the target of a range of effector pathways and drugs; this range will be fully represented here. A number of therapeutic drugs target the Ca2+ channel complex, including the anti-epileptic gabapentinoid and analgesic ziconotide drugs and the pharmaceutical industry is searching for Ca2+ channel blocking drugs, particularly in the pain, epilepsy, ataxia and migraine areas. Such potential future therapies will be discussed here. Scientific disciplines will focus on electrophysiological studies, but will extend to neuroscience, genetics and biochemical areas. The work described will represent advances at the cutting edge of current neuroscience research and is timely and highly appropriate for the Springer book series.